Ayala Pharmaceuticals $20 million at-the-market offering
Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Ayala Pharmaceuticals, Inc. of its shares of common stock for up to an aggregate amount of $20 million. The common stock is listed on the Nasdaq Global Market under the symbol “AYLA.”
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
The Davis Polk corporate team included partner Yasin Keshvargar and associates David Li and Courtney Sohn. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. All members of the Davis Polk team are based in the New York office.